Development Of E/R Trilayered Matrix Tablets Of Indinavir By Design Of Experiment

Abstract

The aim is to develop trilayer matrix tablets incorporated with indinavir for extend drug release. Indinavir trilayer matrix tablets were formulated using Design of experiment software wherein initially 27 formulations (F1-F27) were designed for active layer from which one best formulation was chosen based on drug content, swelling index and in-vitro release studies. The chosen formulation was formulated into extended release trilayered matrix tablet by varying proportions of polymers by direct compression technique and were evaluated for various parameters, the best optimized formulation was further characterized by FTIR, SEM and stability studies. Out of 27 formulations highest drug release was exhibited by F17 (98.68%). Thus, F17 was used for formulation into trilayer matrix tablets (AF17-HF17) of which CF17 was found to exhibit highest values with 97% swelling index, 99.56 % drug content and 98.12 % drug release in 24h and showed zero-order release kinetics and first order for marketed product. CF17 was further characterized by FTIR studies and found to exhibit no interaction with excipients, and no significant changes were observed in drug content and drug release after loading under accelerated stability conditions. Hence indinavir was successfully formulated into trilayer matrix tablet and found to be stable.